A Diabetes Drug Delivery Deal

When deciding whether to approve a drug, the FDA only cares whether it's safe and effective. But once the drug hits the market, a third characteristic -- how the drug is taken -- helps determine whether it obtains blockbuster status.

Most type 2 diabetes patients have started out on oral medications like Bristol-Myers Squibb's (NYSE: BMY  ) Glucophage -- available as generic metformin -- then progressed to injectable insulin. Newer medications like Merck's (NYSE: MRK  ) Januvia sought to put off the inevitable needle pokes by giving patients another oral therapy before heading on to insulin.

Then there's Amylin Pharmaceuticals' (Nasdaq: AMLN  ) Byetta. An analog of the hormone GLP-1, this wonder drug improves glucose levels and helps diabetics shed pounds -- but it has one big problem. Byetta aims to help patients avoid using insulin, but still results in two needle pokes a day, which has put a damper on its sales. Novo Nordisk (NYSE: NVO  ) has tried to best Byetta by developing a competing GLP-1 analog that only needs to be injected once a day.

If one injection a day is better than two, then one injection per week should be seven times better. That's what Amylin and marketing partner Eli Lilly (NYSE: LLY  ) are doing with Byetta. Using Alkermes' (Nasdaq: ALKS  ) microsphere technology, the once-weekly Byetta looked good in trials, although it's still more than a year away from being on the market.

Novo Nordisk isn't waiting idly by to be outdone by once-weekly Byetta, though. The diabetes expert announced yesterday that it's taking drug delivery full circle by attempting to make an oral version of GLP-1-like drugs. It won't be easy; if it were, Amylin, Novo Nordisk, and others would have started there in the first place. But Novo Nordisk thinks it can use Emisphere Technologies' (Nasdaq: EMIS  ) eligen technology to carry GLP-1 drugs across the membranes of the gut and into the bloodstream.

Hold on to your seat, Fools. The GLP-1 drug wars are going to deliver one bumpy ride.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. See all of our latest discoveries with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Eli Lilly is a Motley Fool Income Investor recommendation. The Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 25, 2008, at 7:11 AM, dorfmeister wrote:

    If oral is superior and there is only one oral technology left (offered by ugne.ob). Shouln't that start a bidding war for that one ????? Sanofi, Roche, Merck and who else has something to loose in diabeticss ?

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 671263, ~/Articles/ArticleHandler.aspx, 10/25/2016 7:00:32 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,169.27 -53.76 -0.30%
S&P 500 2,143.16 -8.17 -0.38%
NASD 5,283.40 -26.43 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
AMLN.DL $0.00 Down +0.00 +0.00%
Amylin Pharmaceuti… CAPS Rating: **
ALKS $54.46 Down -2.23 -3.93%
Alkermes CAPS Rating: ****
BMY $49.55 Up +0.32 +0.65%
Bristol-Myers Squi… CAPS Rating: ****
EMIS $1.05 Down +0.00 +0.00%
Emisphere Technolo… CAPS Rating: **
LLY $77.75 Up +0.18 +0.23%
Eli Lilly and Co. CAPS Rating: ***
MRK $61.95 Up +1.20 +1.98%
Merck and Co. CAPS Rating: ****
NVO $40.33 Down -0.48 -1.18%
Novo Nordisk CAPS Rating: *****